XML 22 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 250,728,118 $ 22,196,097
Short-term investments 160,914,935 67,338,017
Accounts receivable 18,559,967 700,073
Accounts receivable from affiliated entities 503,782 1,332,044
Prepaid expenses and other current assets 40,357,456 1,584,598
Prepaid expenses and other current assets from affiliated entities 106,432 1,050,140
Total current assets 471,170,690 94,200,969
Fixed assets, net 11,348,144 12,773,017
Investments in affiliated entities 4,460,366 6,315,356
Investment in Geneos 434,387 0
Intangible assets, net 3,146,770 3,693,851
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 12,741,296 13,783,009
Other assets 25,957,448 2,672,024
Total assets 539,772,472 143,951,597
Current liabilities:    
Accounts payable and accrued expenses 21,203,808 18,237,258
Accounts payable and accrued expenses due to affiliated entities 642,969 729,729
Accrued clinical trial expenses 9,950,345 4,049,727
Deferred revenue 46,628 92,353
Deferred revenue from affiliated entities 0 31,775
Operating lease liability 2,329,394 2,074,842
Grant funding liability 7,474,310 6,065,212
Grant funding liability from affiliated entities 58,500 708,425
Total current liabilities 41,705,954 31,989,321
Deferred revenue, net of current portion 79,214 101,567
Derivative liability 0 8,819,023
Operating lease liability, net of current portion 18,063,515 20,409,922
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 37,500 135,000
Other liabilities 57,663 36,943
Total liabilities 78,631,714 138,546,739
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2020 and 23 at December 31, 2019 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2020 and December 31, 2019, issued and outstanding: 186,851,493 at December 31, 2020 and 101,361,034 at December 31, 2019 186,851 101,361
Additional paid-in capital 1,367,406,869 742,646,785
Accumulated deficit (906,196,812) (739,785,655)
Accumulated other comprehensive income (loss) (256,150) 472,608
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 461,140,758 3,435,099
Non-controlling interest 0 1,969,759
Total stockholders’ equity 461,140,758 5,404,858
Total liabilities and stockholders’ equity 539,772,472 143,951,597
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 14,139,988 64,180,325
Convertible Bonds    
Current liabilities:    
Convertible debt $ 4,515,834 $ 12,842,592